Bodyweight Gain and Anticonvulsants
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 24 (13) , 969-978
- https://doi.org/10.2165/00002018-200124130-00004
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Safety and efficacy of vigabatrin and carbamazepine in ne wly diagnosed epilepsy: a multicentre randomised double-blind studyThe Lancet, 1999
- Bodyweight Change as an Adverse Effect of Drug TreatmentDrug Safety, 1996
- Valproate and palmitate binding to serum albumin in valproate-treated patients. relation to obesityEpilepsy Research, 1993
- Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolismTrends in Neurosciences, 1992
- Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsyActa Neurologica Scandinavica, 1992
- Weight Gain, Increased Appetite, and Excessive Food Intake Induced by CarbamazepineClinical Neuropharmacology, 1991
- Adverse Effects of ValproateEpilepsia, 1984
- Multiple sclerosis, HLA, and lymphocyte surface markersActa Neurologica Scandinavica, 1984
- Effects of sodium valproate in 100 children with special reference to weight.BMJ, 1981
- SODIUM VALPROATE IN the TREATMENT of RESISTANT EPILEPSYActa Neurologica Scandinavica, 1976